Drug Profile
Research programme: Ig fusion GAIM dimers - Proclara Biosciences
Alternative Names: NPT 288; NPT-007; NPT-014; NPT-289Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator NeuroPhage Pharmaceuticals
- Developer Proclara Biosciences
- Class Antidementias; Antiparkinsonians; Immunoglobulin fusion proteins; Neuroprotectants; Neuropsychotherapeutics; Recombinant fusion proteins
- Mechanism of Action Alpha-synuclein modulators; Amyloid beta-protein modulators; Protein aggregation inhibitors; Tau protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Amyloidosis; Neurological disorders; Parkinson's disease
Most Recent Events
- 28 Dec 2023 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route) before December 2023
- 28 Dec 2023 Discontinued - Preclinical for Amyloidosis in USA (unspecified route) before December 2023
- 28 Dec 2023 Discontinued - Preclinical for Parkinson's disease in USA (unspecified route) before December 2023